Publications

July 16, 2017

Cherniakov I, Izgelov D, Barasch D, Davidson E, Domb AJ, Hoffman A (2017) Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration. J Control Release. 266:1-7. doi: 10.1016/j.jconrel.2017.09.011.

Cherniakov I, Izgelov D, Domb AJ, Hoffman A (2017) The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta- 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. Eur J Pharm Sci. 109:21-30. doi: 10.1016/j.ejps.2017.07.003.

 

Udi S, Hinden L, Earley B, Drori A, Reuveni N, Hadar R, Cinar R, Nemirovski A, Tam J (2017) Proximal Tubular Cannabinoid-1 Receptor Regulates Obesity-induced Chronic Kidney Disease. J Am Soc Nephrol.


Tam J, Szanda G, Drori A, Liu Z, Cinar R, Kashiwaya Y, Reitman ML, Kunos G (2017) Peripheral Cannabinoid-1 Receptor Blockade Restores Hypothalamic Leptin Signaling. Mol Metab. doi.org/10.1016/j.molmet.2017.06.010.


Zelber-Sagi S, Azar S, Nemirovski A, Webb M, Halpern Z, Shibolet O, Tam J (2017) Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease. Obesity. 25(1):94-101.


Mechoulam R (2017) Cannabis and epilepsy. Epilepsy Behav. 70(Pt B):278-279.


Rock EM, Limebeer CL, Petrie GN, Williams LA, Mechoulam R, Parker LA (2017) Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats. Psychopharmacology (Berl) 234(14):2207-2217.


Lee WS, Erdelyi K, Matyas C, Mukhopadhyay P, Varga ZV, Liaudet L, Haskó G, Čiháková D, Mechoulam R, Pacher P (2016) Cannabidiol limits T cell-mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation. Mol Med. doi: 10.2119/molmed.2016.00007.


Kozela E, Haj C, Hanuš L, Chourasia M, Shurki A, Juknat A, Kaushansky N, Mechoulam R, Vogel Z (2016) HU-446 and HU-465, Derivatives of the Non-psychoactive Cannabinoid Cannabidiol, Decrease the Activation of Encephalitogenic T Cells. Chem Biol Drug Des. 87(1):143-53.


Shoval G, Shbiro L, Hershkovitz L, Hazut N, Zalsman G, Mechoulam R, Weller A (2016) Prohedonic Effect of Cannabidiol in a Rat Model of Depression. Neuropsychobiology. 73(2):123-9.


Fisher T, Golan H, Schiby G, PriChen S, Smoum R, Moshe I, Peshes-Yaloz N, Castiel A, Waldman D, Gallily R, Mechoulam R, Toren A (2016) In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Curr Oncol. 23(2):S15-22.


Tam J (2016) The emerging role of the endocannabinoid system in the pathogenesis and treatment of kidney diseases. J Basic Clin Physiol Pharmacol. 27(3):267-76.


Mann A, Cohen-Yeshurun A, Trembovler V, Mechoulam R, Shohami E (2016) Are the endocannabinoid-like compounds N-acyl aminoacids neuroprotective after traumatic brain injury? J Basic Clin Physiol Pharmacol. 27(3):209-16.


Juknat A, Kozela E, Kaushansky N, Mechoulam R, Vogel Z (2016) Anti-inflammatory effects of
the cannabidiol derivative dimethylheptyl-cannabidiol - studies in BV-2 microglia and encephalitogenic T cells. J Basic Clin Physiol Pharmacol. 27(3):289-96.


Maslov LN, Khaliulin I, Zhang Y, Krylatov AV, Naryzhnaya NV, Mechoulam R, De Petrocellis L, Downey JM (2016) Prospects for Creation of Cardioprotective Drugs Based on Cannabinoid Receptor Agonists. J Cardiovasc Pharmacol Ther. 21(3):262-72.


Mechoulam R (2016) Cannabis - the Israeli perspective. J Basic Clin Physiol Pharmacol. 27(3):181-7.


Shohami E, Horowitz M. Cannabinoids in Health and Disease (2016) J Basic Clin Physiol Pharmacol. 27(3):175-9.


Breuer A, Haj CG, Fogaça MV, Gomes FV, Silva NR, Pedrazzi JF, Del Bel EA, Hallak JC, Crippa JA, Zuardi AW, Mechoulam R, Guimarães FS (2016) Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects. PLoS One. 11(7):e0158779.


Rock EM, Boulet N, Limebeer CL, Mechoulam R, Parker LA (2016) Cannabinoid 2 (CB2) receptor agonism reduces lithium chloride-induced vomiting in Suncus murinus and nausea-induced conditioned gaping in rats. Eur J Pharmacol. 786:94-9.


Knani I, Earley BJ, Udi S, Nemirovski A, Hadar R, Gammal A, Cinar R, Hirsch HJ, Pollak Y, Gross I, Eldar-Geva T, Reyes-Capo DP, Han JC, Haqq AM, Gross-Tsur V, Wevrick R, Tam J (2016) Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader-Willi syndrome. Mol Metab. 5(12):1187-1199.


Haroutounian S, Ratz Y, Ginosar Y, Furmanov K, Saifi F, Meidan R, Davidson E (2016) The Effect of Medicinal Cannabis on Pain and Quality-of-Life Outcomes in Chronic Pain: A Prospective Open-label Study. Clin J Pain. 32(12):1036-1043.